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ABSTRACT
Introduction: To investigate the pattern of
vancomycin-associated nephrotoxicity in
children and to examine potential predisposing
factors for nephrotoxicity, including average
serum trough concentrations C10 lg/mL.
Methods: Patients C1 week old to B15 years
with normal baseline serum creatinine values
who received vancomycin for C48 h between
October 2010 and September 2012 were
retrospectively evaluated. Nephrotoxicity was
defined as a serum creatinine increase of
C0.5 mg/dL or C50% baseline increase over
2 days. Patients with average serum trough
concentrations C10 lg/mL were compared
with a lower trough group.
Results: Renal toxicity occurred in 72 (27.2%)
of the 265 studied pediatric cases. High trough
vancomycin levels C10 lg/mL were presented
in 59 pediatric patients suffering from
nephrotoxicity. Using multiple regression
analysis, cases admitted to the intensive care
unit (ICU) and to whom aminoglycoside
medication was administered concurrently
with vancomycin medication showed a
significant high renal toxicity incidence [odds
ratio (OR) 2.91; 95% confidence interval (CI)
1.70, 8.61; P value\0.03)] and (OR 9.11; 95% CI
4.11, 24.13; P\0.05), respectively.
Conclusion: Renal function tests and
continuous monitoring of vancomycin trough
levels for children receiving vancomycin
therapy, especially admitted to the ICU and
given other aminoglycoside medications, are
essential.
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INTRODUCTION
Vancomycin is a bactericidal glycopeptide
antibiotic widely used in children for treating
methicillin-resistant Staphylococcus aureus
(MRSA) infections [1]. In fact, vancomycin
trough serum concentrations between 10 and
15 lg/mL have been recommended for serious
infections caused by MRSA (including
endocarditis, osteomyelitis, meningitis, and
pneumonia) [2, 3]. Although this consensus
statement excluded recommendations for
children, aggressive vancomycin dosing
regimens are nonetheless being used with
pediatric patients. This dosing may increase
the incidence of nephrotoxicity in children.
Vancomycin-associated renal toxicity has
been a point of controversy since 1958, when
Geraci et al. [4] published the first case series
linking to nephrotoxic effects of vancomycin.
Since then, several studies have reported an
association between vancomycin serum trough
concentrations and renal toxicity [5–7].
Although vancomycin has been associated
with nephrotoxicity, causality has not been
firmly established. Data in adult patients
indicate that higher vancomycin doses (or
higher serum trough concentrations) are
associated with increased nephrotoxicity
[8–10]. Nephrotoxicity data associated with
higher vancomycin trough attainment through
aggressive dosing in the pediatric population are
lacking, although nephrotoxicity incidence rates
might be higher with increased troughs, as
evident in adults.
However, the definition of renal toxicity, as
well as the patient population and disease
severity, has varied among these studies.
Therefore, the authors performed a
retrospective, observational clinical study with
the main goal of determining the overall
incidence rate and predisposing factors
associated with development of nephrotoxicity
in children receiving vancomycin, including
those achieving high average vancomycin
serum trough concentrations of C10 lg/mL.
METHODS
Study Setting
This study was conducted at Dammam
Maternal and Child Hospital (DMCH), a
community-based, secondary care hospital. All
pediatric patients receiving vancomycin are
routinely monitored according to guidelines
by toxicologists who perform pharmacokinetic
analyses to assess toxicity and goal trough
attainment. All Dammam Poison Control
Center (DPCC) clinical toxicologists are
trained, and have undergone internal
competency training and testing in making
pharmacokinetic calculations both by manual
calculation and with the use of an institution-
based computer kinetic program. Steady-state
serum trough concentrations are generally
obtained; baseline and periodic serum
creatinine (SCr) values are monitored in all
patients.
Inclusion and Exclusion Criteria
In the present retrospective study, eligible
pediatric patients were C1 week old (and not
born prematurely before 37 weeks gestational
age) to B15 years of age; had received
vancomycin for at least 48 h between October
2010 and September 2012, and had normal
baseline SCr values (defined as B0.6 mg/dL for
patients B1 month old and B0.9 mg/dL for
those [1 month old). The definition of normal
renal function was applied to the start of
vancomycin therapy. Patients were required to
38 Infect Dis Ther (2013) 2:37–46
123
have had one or more serum vancomycin
concentrations and repeat SCr values.
Premature neonates and infants cared for in
the neonatal intensive care unit (ICU) were
excluded because DMCH used a separate dosing
guideline, and the low muscle mass of these
infants may impair prediction of renal
impairment.
Study Design
A retrospective cohort design was employed to
assess the effect of vancomycin serum trough
concentrations on the occurrence of renal
toxicity. The study protocol was approved by
the DPCC review board, with complete
confidentiality of patient information records
as maintained by keeping patients names
anonymous. This article does not contain any
studies with human or animal subjects
performed by any of the authors. Patients were
identified using the toxicology clinical
monitoring database Online Analytical
Toxicology Request and Result (OTARR). Only
the first course of vancomycin was evaluated if
multiple courses were given during the study
period. Electronic medical records and
pharmacokinetic monitoring forms were
reviewed. Pertinent data, including
demographics, laboratory details, vancomycin
dosing, and pharmacokinetics, were collected
on standardized forms. Concomitant use of
nephrotoxins, such as aminoglycosides,
cyclosporine, tacrolimus, furosemide, or
amphotericin, was recorded. The DMCH
protocol for intravenous administration of
vancomycin requires measurement of steady-
state trough concentrations, with a target of
5–10 lg/mL for both serious and non-serious
infectious status.
A MEDLINE search was performed using the
keywords ‘‘vancomycin,’’ ‘‘renal toxicity,’’ ‘‘renal
failure,’’ ‘‘creatinine,’’ and ‘‘creatinine
clearance.’’ Based on this literature review,
renal toxicity was defined as either a C0.5 mg/
dL increase from baseline in SCr or a C50%
increase from baseline in SCr based on serial SCr
measurements over 2 days [8, 9]. Baseline SCr
and age- and sex-adjusted creatinine clearance
calculations were made before administration
of vancomycin in all patients, using the
following formula [10]: Estimated creatinine
clearance = (140 - age) (weight in kg)/
(72 9 serum creatinine) 9 0.085 (women only).
Grouping of the Studied Patients
An average vancomycin trough level was
calculated using all measured serum
concentration results throughout therapy.
Baseline vancomycin clearance (L/h) was
obtained from pharmacokinetic values from the
first steady-state vancomycin concentration,
using the population volume of distribution.
High trough therapy was defined as an average
serum trough concentration of C10 lg/mL and
low trough therapy as an average serum
trough concentration of \10 lg/mL for all
concentrations throughout therapy.
Statistical Analysis
All comparisons were unpaired, and all tests of
significance were two-tailed. Continuous
variables were compared using the Student
t test for normally distributed variables, and
the Mann–Whitney U test for non-normally
distributed variables. The Chi-square test was
used to compare categoric variables. The
primary data analysis compared patients who
met the study definition for renal toxicity with
those who did not. Values were expressed as
mean (±SD) for continuous variables and as a
percentage of the group from which they were
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derived for categoric variables. P value was two-
tailed, and P B 0.05 was considered statistically
significant. The authors performed multiple
logistic regression analyses using SPSS for
Windows version 19.0 (SPSS Inc., Chicago, IL,
USA). Multivariate analysis was performed using
models that were judged a priori to be clinically
sound [11]; this was prospectively determined
to be necessary to avoid producing spuriously
significant results with multiple comparisons.
All potential risk factors that were significant at
the 0.2 level in univariate analyses were entered
into the model. A stepwise approach was used
to enter new terms into the logistic regression
model, in which renal toxicity was the
dependent outcome variable and 0.05 was set
as the limit for the acceptance or removal of
new terms.
RESULTS
Table 1 shows the demographic and clinical data
characteristics of the studied pediatric cases
receiving vancomycin therapy. The total
number of cases was 265, of which 130 were
male. Gender factor had no clinically significant
difference between high and low trough
vancomycin levels. Some parameters in the
studied table showed a significant difference
when comparing a low vancomycin trough level
\10 lg/mL with a high vancomycin level
C10 lg/mL; these were mean age (P[0.030),
meningitis (P[0.026), dermal infectious status
(P[0.031), mean initial (P = 0.001) and overall
(P = 0.032) vancomycin dosage, and frequency
of ICU admitted cases (P = 0.041). Other
parameters showed a non-significant difference
when comparing a low vancomycin trough level
\10 lg/mL with a high vancomycin level
C10 lg/mL; these were bacteremia, pneumonia,
myocarditis, arthritis, endocarditis, malignancy,
former prematurity, congenital heart disease,
respiratory disease, and respiratory distress
syndrome.
Table 2 presents the variable parameters
related to the renal profile in children
receiving vancomycin therapy. Parameters that
showed a significant difference were the
frequency of nephrotoxicity (P = 0.0001),
mean time of occurrence of nephrotoxicity
(P = 0.042), mean vancomycin dose at toxicity
time (P = 0.031), mean peak (P = 0.033) and
end (P = 0.024) of therapy SCr levels, frequency
of very high increase SCr level above baseline
([0.5 mg/dL) (P = 0.001), and mean
vancomycin clearance rate at peak (P = 0.029)
and end (P = 0.043) of vancomycin medication
course. Renal toxicity occurred in 72 (27.2%) of
the 265 studied pediatric cases.
The effect of the mean vancomycin trough
level, duration of vancomycin therapy, mean
SCr level, mean vancomycin clearance, and
concomitant nephrotoxin medication are
clearly shown in Table 3. The percentage of
nephrotoxicity occurrence clearly shows a
significant difference in the previously
mentioned predisposing factors (mean
vancomycin trough level, P = 0.002; duration
of vancomycin therapy, P = 0.041; mean SCr
level, P = 0.000; mean vancomycin clearance
change, P = 0.029; and concomitant amino
glycosides, P = 0.001).
Using multiple regression analysis, cases
admitted to the ICU and to whom
aminoglycoside medication was administered
concurrently with vancomycin medication
showed a significant high renal toxicity
incidence [odds ratio (OR) 2.91; 95% confidence
interval (CI) 1.70, 8.61; P value \0.03)] and (OR
9.11; 95% CI 4.11, 24.13; P\0.05), respectively.
Figure 1 shows the percentage of renal
toxicity according to the vancomycin trough
level. The highest percentage was found in the
40 Infect Dis Ther (2013) 2:37–46
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Table 1 Demographic, baseline, and patients characteristic of children receiving vancomycin (total n = 265)
Characteristics Low trough (n5 166) High trough (n 5 99) P value
Male, n (%) 82 (49.4) 48 (48.5) 0.263
Mean age, years (±SD) 2.1 ± 1.9 1.7 ± 1.3 0.030*
Mean weight, kg (±SD) 7.37 ± 11.7 6.1 ± 7.4 0.188
Infection type, n (%)
Bacteremia 72 (43.4) 47 (47.5) 0.35
Pneumonia 66 (39.8) 28 (28.2) 0.833
Meningitis 7 (4.2) 13 (13.1) 0.026*
Dermal infection 6 (3.6) 12 (12.1) 0.031*
Myocarditis 5 (3.0) 4 (4.0) 0.435
Arthritis 6 (3.6) 7 (7.1) 0.712
Endocarditis 4 (2.4) 2 (2.0) 0.551
Culture positive for MRSA, n (%) 31 (18.7) 11 (11.1) 0.327
Chronic illness, n (%)
Malignancy 5 (3.0) 11 (11.1) 0.672
Former prematurity 21 (12.7) 16 (16.2) 0.183
Congenital heart disease 11 (6.6) 13 (13.1) 0.417
Respiratory disease 12 (7.2) 7 (7.1) 0.123
Respiratory distress syndrome 11 (6.6) 2 (2.0) 0.327
Concomitant nephrotoxin, n (%)
Aminoglycosides 52 (31.3) 12 (12.1) 0.051
Cyclosporine 6 (3.6) 3 (3.0) 0.341
Tacrolimus 3 (1.8) 1 (1.0) 0.360
Non-steroidal anti-inﬂammatory 17 (10.2) 10 (10.1) 0.172
Amphotericin 3 (1.8) 3 (3.0) 0.562
Loop diuretic ‘‘furosemide’’ 22 (13.3) 18 (18.2) 0.342
Initial vancomycin dose, mg/kg/day
Mean (±SD) 36.1 (24.6) 47.4 (15.5) 0.001*
Overall vancomycin dose therapy, mg/kg/day
Mean (±SD) 32.2 ± 22.3 41.2 ± 17.3 0.032*
Duration of vancomycin therapy, days
Mean (±SD) 12.1 ± 8.4 14.4 ± 5.1 0.120
Duration of hospital stay, days
Mean (±SD) 17.2 ± 14.1 22.4 ± 15.1 0.471
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vancomycin trough level therapy [15 lg/mL
(87.5%), with a significant difference when
compared with low vancomycin trough level
\10 lg/mL (P\0.001).
DISCUSSION
MRSA infection in children is treated mainly
by vancomycin, a bactericidal glycopeptide
antibiotic. There are two medical protocols
regarding the use of vancomycin therapy in
the treatment of serious infection caused by
MRSA. One of these suggests keeping the trough
serum vancomycin concentration at 5–10 lg/
mL, as with other non-serious infections, and
the other advises increasing the vancomycin
level to between 10 and 15 lg/mL. The protocol
applied in DMCH is the first vancomycin
Table 2 Renal kinetics proﬁle in children receiving vancomycin
Parameters Low trough (n 5 166) High trough (n 5 99) P value
Nephrotoxicity during therapy, n (%) 13 (7.8) 59 (59.6) 0.0001*
Time of nephrotoxicity, days mean (±SD) 6.3 (3.7) 3.2 (1.4) 0.042*
Vancomycin dose at toxicity time, mg/kg mean (±SD) 33.6 (10.1) 46.2 (13.7) 0.031*
Serum creatinine level, mg/dL mean (±SD)
Baseline 0.57 (0.2) 0.67 (0.51) 0.325
Peak 0.68 (0.3) 0.81 (0.34) 0.033*
End of therapy 0.54 (0.7) 0.62 (0.6) 0.024*
Serum creatinine C0.5 mg/dL above baseline, n (%) 4 (2.4) 19 (19.2) 0.001*
Vancomycin clearance, L/h mean (±SD)
Baseline 2.2 (2.1) 1.9 (1.1) 0.231
Peak 1.85 (1.7) 1.53 (0.7) 0.029*
End of therapy 2.1 (1.9) 1.81 (1.3) 0.043*
Total renal toxicity incidence in 265
studied pediatric cases, n (%)
72 (27.2%)
* P value signiﬁcant B0.05
Table 1 continued
Characteristics Low trough (n5 166) High trough (n 5 99) P value
Range 6–24 9–41
ICU admission
n (%) 38 (22.9) 37 (37.4) 0.041*
Duration stay, days (±SD) 15.3 (12.1) 9.3 (4.1) 0.371
ICU intensive care unit, MRSA methicillin-resistant Staphylococcus aureus, SD standard deviation
* P value signiﬁcant B0.05
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protocol that keeps the trough level between
5–10 lg/mL.
The present study was performed to clarify
the vague relationships among different
variables in the studied pediatric cases, such as
age, weight, indication of vancomycin therapy,
admission status, duration of therapy,
concomitant nephrotoxin usage with
vancomycin medication, vancomycin dosage
and trough level, and renal functions status in
studied children. The definition of renal failure
terminology applied in the current study
followed that in many documented references
[8–10] as previously mentioned.
In the studied literature, the incidence of
renal failure in adult patients treated with
vancomycin ranged from 12% to 42%, and
Fig. 1 Incidence of renal toxicity stratiﬁed by vancomycin
steady-serum trough concentration
Table 3 Vancomycin therapy and changes in renal functions






Mean (±SD) 8.4 (3.1) 17.1 (4.7) 0.002*
Frequency, mean (range) 5.3 (3–7) 7.4 (4–13) 0.536
Duration of vancomycin therapy[14 days,
n (%)
13 (13.8) 31 (43.1) 0.041*
Serum creatinine level, mg/dL mean (±SD)
Maximum 0.56 (0.4) 0.91 (0.37) 0.000*
Change 0.12 (0.2) 0.83 (0.22) 0.000*
Vancomycin clearance, L/h mean (±SD)
Minimum 2.4 (2.2) 1.7 (0.9) 0.231
Change 0.2 (0.03) 1.1 (0.01) 0.029*
Concomitant nephrotoxins, n (%)
Aminoglycosides 26 (27.7) 38 (52.8) 0.001*
Cyclosporine 3 (3.2) 6 (8.3) 0.728
Tacrolimus 2 (2.1) 2 (2.8) 0.921
Non-steroidal anti-inﬂammatory 6 (6.4) 11 (15.3) 0.414
Amphotericin 1 (1.1) 4 (5.6) 0.827
Loop diuretic ‘‘furosemide’’ 17 (18.1) 23 (31.9) 0.071
* P value signiﬁcant B0.05
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this percentage was markedly elevated to reach
its maximum percentage (42%) when other
aminoglycoside medications were used with
vancomycin therapy [12, 13].
In the present study, 27.2% of the studied
children suffered from renal toxicity during
vancomycin therapy, and the incidence of
renal toxicity increased when the vancomycin
trough level became [10–15 lg/mL (41%) and
reached its peak in 87.5% of cases with serum
trough vancomycin levels of [15 lg/mL. In
accordance with the presented figures, several
adult and pediatric studies documented the
previously noted information [8, 14].
In the present study, other factors have been
reported that can affect the incidence of
occurrence of renal toxicity beside the
vancomycin serum level. These include
duration of vancomycin therapy, concomitant
usage of aminoglycosides, ICU admission
status, presence of bacterial meningitis,
presence of bacterial dermal infection, age,
and weight of the studied pediatric cases.
In the present study of 72 cases suffering
from renal toxicity, there were 38 pediatric cases
who were given aminoglycosides as well as
vancomycin therapy. About one-third (37.4%)
of the studied pediatric cases with high
vancomycin trough levels were admitted to
the ICU. The studied pediatric cases with high
vancomycin trough levels of C10 lg/dL were
associated with high mean overall vancomycin
dose (41.2 mg/kg/d) when compared with low
trough level \10 lg/mL (32.2 mg/kg/d), with a
significant difference (P = 0.032). In accordance
with the present results, one study of adult cases
found a significant nephrotoxicity percentage
among patients receiving a high dose of
vancomycin therapy and who were admitted
to the ICU [15].
In the present study, most of the pediatric
cases suffering from nephrotoxicity induced by
vancomycin therapy were associated with a
significant increasing SCr level that returned
to the average baseline concentration at the end
of therapy or hospital discharge. In accordance
with the present findings, one study by Jeffries
et al. [9] stated that 72% of the studied cases of
patients suffering from vancomycin-induced
nephrotoxicity had a high creatinine level that
returned to baseline at the time of hospital
discharge.
Regarding the time of occurrence of
vancomycin-induced renal toxicity, several
studies reported that the onset of renal toxicity
mainly occurs after a lapse of 1–3 weeks from the
onset of vancomycin therapy in adult patients
[2, 9, 10]. In the present study, the time of
occurrence of renal toxicity occurred in the first
week for renal toxicity associated with both high
and low trough vancomycin levels.
The duration of vancomycin therapy plays
an important role in the induction of
vancomycin-induced nephrotoxicity. Hidayat
et al. [2] stated that increasing the duration of
vancomycin therapy was associated with an
increase in the incidence of occurrence of renal
toxicity, and approximately 30% of the studied
cases associated with nephrotoxicity were
patients receiving vancomycin therapy for
more than 14 days, while it was only 6.3% in
adult patients receiving vancomycin therapy for
less than 1 week.
CONCLUSION
The present work discussed the impact of
vancomycin therapy in the renal function of the
pediatric population. The result of this study
showed that vancomycin-induced renal toxicity
existed in 27.2% of the studied cases, and the
incidence of renal toxicity was significantly
increased with high trough vancomycin levels of
44 Infect Dis Ther (2013) 2:37–46
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C10 lg/mL. Admission to the ICU, prolongation
of vancomycin therapy, and concurrent
administration of other aminoglycoside
medications during vancomycin therapy
increased the incidence of renal toxicity in
pediatric studied cases. In conclusion, renal
functions tests and continuous monitoring of
vancomycin trough levels for children receiving
vancomycin therapy, especially admitted to the
ICU and given other aminoglycoside
medications, are essential.
ACKNOWLEDGMENTS
No funding or sponsorship was received for this
study or publication of this article. Dr. Ahmed
Refat Ragab is the guarantor for this article, and
takes responsibility for the integrity of the work
as a whole.
Conflict of interest. Ahmed R. Ragab, Maha
K. Al-Mazroua, and Mona A. Al-Harony declare
no conflict of interest.
Compliance with Ethics Guidelines. This
article does not contain any studies with
human or animal subjects performed by any of
the authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Gerber JS, Coffin SE, Smathers SA, Zaoutis TE.
Trends in the incidence of methicillin-resistant
Staphylococcus aureus infection in children’s
hospitals in the United States. Clin Infect Dis.
2009;49:65–71.
2. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-
Beringer A. High dose vancomycin therapy for
methicillin-resistant Staphylococcus aureus
infections: efficacy and toxicity. Arch Intern Med.
2006;166:2138–44.
3. Ryback M, Lomaestro B, Rotschafer JC, et al.
Therapeutic monitoring of vancomycin in adult
patients: a consensus review of the American
Society of Health-System Pharmacists, the
Infectious Diseases Society of American, and the
Society of Infectious Diseases Pharmacists. Am J
Health Syst Pharm. 2009;66:82–98.
4. Geraci JE, Heilman FR, Nichols DR, Wellman WE.
Antibiotic therapy of bacterial endocarditis. VII.
Vancomycin for acute micrococcal endocarditis:
preliminary report. Proc Staff Meet Mayo Clin.
1958;33:172–81.
5. Kralovicova K, Spanik S, Halko J. Do vancomycin
serum levels predict failures of vancomycin therapy
or nephrotoxicity in cancer patients? J Chemother.
1997;9:420–6.
6. Zimmermann AE, Katona BG, Plaisance KI.
Association of vancomycin serum concentrations
with outcomes in patients with gram-positive
bacteremia. Pharmacotherapy. 1995;15:85–91.
7. Elting LS, Rubenstein EB, Kurtin D, et al. Mississippi
mud in the 1990s: risks and outcomes of
vancomycin-associated toxicity in general
oncology practice. Cancer. 1998;83:2597–607.
8. Hermsen ED, Hanson M, Sankaranarayanan J,
Stoner JA, Florescu MC, Rupp ME. Clinical
outcomes and nephrotoxicity associated with
vancomycin trough concentrations during
treatment of deep-seated infections. Expert Opin
Drug Saf. 2010;9:9–14.
9. Jeffries MN, Isakow W, Doherty JA, Micek ST, Kollef
MH. A retrospective analysis of possible renal
toxicity associated with vancomycin in patients
with health care-associated methicillin-resistant
Staphylococcus aureus pneumonia. Clin Ther.
2007;29:1107–15.
10. Lodise TP, Lomaestro B, Graves J, Drusano GL.
Larger vancomycin doses (at least 4 grams per day)
are associated with an increased incidence of
nephrotoxicity. Antimicrob Agents Chemother.
2008;52:1330–6.
11. Concato J, Feinstein AR, Holford TR. The risk of
determining risk with multivariable models. Ann
Intern Med. 1993;118:201–10.
Infect Dis Ther (2013) 2:37–46 45
123
12. American Thoracic Society. Infectious Diseases
Society of America. Guidelines for the management
of adults with hospital-acquired, ventilator-
associated, and healthcare-associated pneumonia.
Am J Respir Crit Care Med. 2005;171:388–416.
13. Lodise TP, Patel N, Lomaestro BM, Rodvold KA,
Drusano GL. Relationship between initial
vancomycin concentration-time profile and
nephrotoxicity among hospitalized patients. Clin
Infect Dis. 2009;49:507–14.
14. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar
PH. Nephrotoxicity of vancomycin, alone and with
aminoglycoside. J Antimicrob Chemother.
1990;25:679–87.
15. Kollef MH, Rello J, Cammarata SK. Clinical cure
and survival in Gram-positive ventilator-associated
pneumonia: retrospective analysis of two double-
blind studies comparing linezolid with
vancomycin. Intensive Care Med. 2004;30:388–94.
46 Infect Dis Ther (2013) 2:37–46
123
